Rankings / Mitochondria & Cellular Energy

Methylene blue

Mitochondria & Cellular Energy · Alternative electron carrier / MAOI / tau aggregation inhibitor

Tier C

High-risk evidence profile

Reviewed by Read Off Label · Last reviewed · How we grade

mitochondrialmao-inhibitortau-aggregation-inhibitoralzheimerprescriptionotc
High-risk evidence profile
4.9 / 10
Tier C
Ev 6 Bn 5 Sf 3.5

Bottom line

Read Off Label grades Methylene blue as C (4.9/10) based on moderate evidence, med benefit magnitude, and a med-high-risk safety profile.

Its high-risk evidence profile reflects a Safety score of 3.5/10; reported benefits and harms can differ by indication, dose, route, duration, and population.

Dose-response is a central uncertainty; reported biohacker protocols commonly cite 0.

Studied, labeled, or reported-use context: 0. — Rx (methemoglobinemia, cyanide poisoning, ifosfamide encephalopathy); USP/pharma grade is marketed OTC in many jurisdictions as "longevity" supplement; product-grade verification varies; not individualized guidance.

What the evidence says

Dose-response is a central uncertainty; reported biohacker protocols commonly cite 0.5-2 mg/kg PO, while the cited studies span different formulations and doses. Industrial, aquarium, and photographic grades can contain heavy-metal contaminants; human studies use USP/pharmaceutical-grade material. Mechanism updated in light of newer literature: MB acts as an alternative electron carrier between NADH and cytochrome c, bypassing complex I deficits common in aging and neurodegeneration. **2024-2025 development — major reversal of prior framing**: TauRx LUCIDITY Phase 3 of hydromethylthionine mesylate (HMTM, the reduced LMTX form) at 16 mg/day in MCI and mild-to-moderate AD reported 82% reduction in ADAS-cog13 decline at 18 months (115% reduction in early-AD subgroup); 71% of patients had same or better global CDR at 2 years vs 52% for matched placebo; 35% reduction in brain atrophy. **Caveat**: independent analysts (Clinical Trials Arena AD/PD 2025 commentary) flag that LUCIDITY's "placebo" arm received background standard-of-care AD therapy rather than true placebo — making the effect-size estimate disputed. TauRx submitted UK marketing application July 2024; US/Canada filings announced for 2026. This **supersedes** the prior framing — the 2016 Gauthier TRx0237 Ph3 (higher 75-125 mg BID dose) failed primary endpoint and was the earlier disappointment; the dramatically lower 16 mg/day appears critical to LMTX's signal. Industry-funding caveat: all LMTX/HMTM trials are TauRx-funded; independent replication remains the open question. For biohacker cognitive use (vs. AD), the Rodriguez 2016 fMRI signal at 280 mg ≈ 4 mg/kg is the principal cited human anchor — modest and short-term.

Mechanism

Hormetic dose-response: at low doses (~0.5-4 mg/kg) reroutes electrons from NADH directly to cytochrome c, increasing complex IV activity and ATP synthesis (~30-40% in vitro) while reducing oxidative stress; at high doses becomes pro-oxidant and can paradoxically cause methemoglobinemia; reversible MAO-A inhibitor (~700x more potent than linezolid); MAO-B inhibitor; tau aggregation inhibitor; crosses BBB; reduces β-amyloid and phospho-tau via enhanced mitophagy in preclinical models

Studied, labeled, or reported dose & route

0.5-4 mg/kg PO (hormetic — higher doses counterproductive for cognition; LUCIDITY used 16 mg/day fixed dose ≈ 0.2 mg/kg in 70 kg adult)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Methylene blue's effects?
Read Off Label rates the evidence for Methylene blue as Moderate and the benefit magnitude as med, producing an overall grade of C (4.9/10). Dose-response is a central uncertainty; reported biohacker protocols commonly cite 0.
What safety findings are reported for Methylene blue?
Methylene blue has a med-high risk profile in the database. Med-High (serotonin syndrome risk with SSRIs/SNRIs/MAOIs via potent MAO-A inhibition — contraindicated within ~5-week SSRI washout for IV doses ≥1 mg/kg; G6PD deficiency causes severe hemolysis — absolute contraindication; methemoglobinemia at supratherapeutic doses; blue discoloration of urine/saliva/skin; staining of teeth and tongue at oral doses) Legal status: Rx (methemoglobinemia, cyanide poisoning, ifosfamide encephalopathy); USP/pharma grade is marketed OTC in many jurisdictions as "longevity" supplement; product-grade verification varies.
What does the low Safety score for Methylene blue represent?
The Safety score is 3.5/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
What doses or routes are reported for Methylene blue?
0.5-4 mg/kg PO (hormetic — higher doses counterproductive for cognition; LUCIDITY used 16 mg/day fixed dose ≈ 0.2 mg/kg in 70 kg adult) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Methylene blue work?
Hormetic dose-response: at low doses (~0.5-4 mg/kg) reroutes electrons from NADH directly to cytochrome c, increasing complex IV activity and ATP synthesis (~30-40% in vitro) while reducing oxidative stress; at high doses becomes pro-oxidant and can paradoxically cause methemoglobinemia; reversible MAO-A inhibitor (~700x more potent than linezolid); MAO-B inhibitor; tau aggregation inhibitor; crosses BBB; reduces β-amyloid and phospho-tau via enhanced mitophagy in preclinical models

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.